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β-thalassemia major (βTM) or Cooley anemia is characterized by signiﬁcantly reduced or absent synthesis of β-globin chains,
which induces important pathologic consequences including hemolytic anemia, altered erythropoiesis, and bone marrow
overstimulation.ThepathogenesisofbonechangesinpatientswithβTMisnotyetcompletelyunderstood.However,anunbalance
in bone mineral turnover resulting from increased resorption and suppression of osteoblast activity has been detected in βTM
patients. The abnormal regulation of bone metabolism may be related to hormonal and genetic factors, iron overload and iron
chelation therapy, nutritional deﬁcits, and decreased levels of physical activity. Here, we review the most recent ﬁndings on the
physiopathology of bone abnormalities in βTM. Clinical presentation and radiological features of βTM-related bone changes are
also discussed.
1.Introduction
β-thalassemia, ﬁrstly described by Cooley and Lee [1],
comprises a group of inherited, autosomal, recessive, and
hematologic disorders characterized by decreased or absent
synthesis of β-globin chains. The mature hemoglobin (Hb)
molecule is a tetramer composed of two α-globin and two
β-globin chains, along with a heme prosthetic group. β-
globin synthesis is controlled by one gene located on each
chromosome 11 [2]. Defects are usually secondary to point
mutations and rarely occur as a consequence of deletions
[2]. In β-thalassemia, β-globin chain production can range
from near to normal to completely absent, leading to varying
degrees of excess α-globin chains and disease severity [2]. β-
thalassemia trait (minor), resulting from heterozygosity for
β-thalassemia, is clinically asymptomatic and manifests with
microcytosis and mild anemia. β-thalassemia intermedia
comprisesaclinicallyandgenotypicallyheterogeneousgroup
of disorders, ranging in severity from the asymptomatic
carrier state to severe, transfusion-dependent disease. β-
thalassemia major (βTM) or Cooley anemia is characterized
by severely reduced or absent synthesis of β-globin chains
from both genes, with symptoms and signs beginning at
about six months of age (abdominal swelling, growth retar-
dation, irritability, jaundice, pallor, skeletal abnormalities,
and splenomegaly) [2].
In βTM, the defective synthesis of β chains, together
with excess α chains, leads to hemolytic anemia, altered ery-
thropoiesis, reduced erythrocyte survival, and bone marrow
overstimulation [1–4]. Patients need blood transfusions to
correct anemia and iron-chelating therapy to control iron
overload[1–4].Anemia,excessbodyiron,andiron-chelation
therapy can result in endocrine disorders (e.g., diabetes mel-
litus, hypogonadism, hypothyroidism, hypoparathyroidism,
hypopituitarism, and Addison’s disease), growth retardation,
liver and cardiac failure, and splenomegaly. The latter can
worsen anemia and occasionally causes thrombocytopenia
andneutropenia,therebyincreasingtheriskofinfectionsand
hemostatic disorders [2–5]. Heart failure is the leading cause
of death in patients with βTM [3, 6].
2. Epidemiology
The worldwide prevalence of α-a n dβ-thalassemia trait
is 1.7% [4]. Males and females are equally aﬀected. The2 Anemia
incidence of thalassemia trait is 4.4 per 10,000 live births [4].
β-thalassemia in its various presentations is more common
in the Mediterranean area, Africa, and Southeastern Asia.
3. Pathogenesis of Bone Changes
inβ-Thalassemia
The pathogenesis of bone changes in βTM patients is not
yet completely understood [7]. In spite of the improved
treatment of the hematologic disorder and its complications,
β-thalassemia patients exhibit an unbalance in bone mineral
turnover with increased resorptive rates and suppression
of osteoblast activity, resulting in diminished bone mineral
density (BMD) more evident in the lumbar spine [8,
9]. Putative mechanisms involved in the pathogenesis of
bone abnormalities in βTM are discussed in the following
subsections.
3.1. Impairments in Osteoblast Activity. Mahachoklertwat-
tana et al. [7, 10] reported growth retardation and delayed
bone age, reduced BMD (especially of the lumbar spine),
and low serum IGF-I levels in children and adolescents
with βTM. In these patients, bone histomorphometry
revealed increased osteoid thickness and delayed osteoid
maturation and mineralization, indicating impaired bone
matrix maturation and defective mineralization [7]. In
addition, iron depots were detected along mineralization
fronts and osteoid surfaces, while focal-thickened osteoid
seamswerefoundtogetherwithirondeposits.Dynamicbone
formation studies revealed reduced bone formation rates.
These ﬁndings indicate that delayed bone maturation and
focal osteomalacia contribute to the pathogenesis of bone
disease in suboptimally blood-transfused βTM patients with
iron overload. Iron depots within bones and low circulating
IGF-I levels may partly contribute to skeletal abnormalities
[7].
Morabito et al. [11] showed that βTM patients displayed
an unbalanced bone turnover, characterized by enhanced
resorption rates (indicated by high levels of pyridinium
cross-links) and a decreased neoformation phase (evidenced
by low levels of osteocalcin, an osteoblast-derived protein)
[11]. Voskaridou and colleagues [12] found increased serum
levels of Dickkopf-1 (Dkk1), a soluble inhibitor of wingless
type (Wnt) signaling, and sclerostin [13], a Wnt inhibitor,
speciﬁcally expressed by osteocytes, in βTM patients. Higher
circulating levels of Dkk1 and sclerostin correlated with
reduced bone mineral density of lumbar spine and distal
radius as well as with increased bone resorption and
reduced bone formation markers. These ﬁndings indicate
that disruption of Wnt signaling in patients with thalassemia
and osteoporosis leads to osteoblast deregulation. Therefore,
sclerostin and Dkk-1 have been proposed as potential
targets for treatment in patients with thalassemia-induced
osteoporosis [13].
3.2. Abnormal Osteoclast Activity. Besides impairments in
osteoblast activity, which are thought to be a major cause
of osteopenia/osteoporosis in βTM, an enhanced activation
of osteoclasts is also invoked as a contributing factor [14].
This provides the rationale for the use of bisphosphonates,
which are potent inhibitors of osteoclast function, for the
management of βTM-induced osteoporosis [15].
An association between increased circulating levels of
proresorptive cytokines and altered bone turnover has
been detected in βTM patients [16]. The receptor acti-
vator of nuclear factor-kappa B (RANK)/RANK ligand
(RANKL)/osteoprotegerin (OPG) pathway has recently been
recognized as the ﬁnal, dominant mediator of osteoclast
proliferation and activation [9]. The OPG/RANKL system
acts as an important paracrine mediator of bone metabolism
also in thalassemic patients. Indeed, these patients showed
no diﬀerences in plasma levels of OPG in the presence
of higher circulating levels of RANKL, with consequent
lower OPG/RANKL ratio and increased osteoclastic activity
[16]. Urinary levels of pyridinium cross-links, a marker
of bone resorption, were higher in βTM patients than
controls and were positively correlated with plasma levels
of RANKL, pointing to a central role of the OPG/RANKL
system in development of bone abnormalities in βTM.
It is suggested that the OPG/RANKL pathway may be
involved in mediating the skeletal actions of sex steroids
in βTM patients, as indicated by the negative correlation
existing between serum levels of RANKL and sex hormones
[16]. Therefore, the improvement of patient compliance to
hormonal replacement therapy could correct the alterations
of the OPG/RANKL system, potentially normalizing bone
turnover. Furthermore, since the degree of bone resorption
dependsonHblevelsandtheseverityofhypogonadism,ade-
quatehormonalreplacementtherapyandannualmonitoring
of bone conditions may be of beneﬁt in young adult βTM
patients [17].
The negative relationship between Hb and RANKL levels
as well as between erythropoietin and OPG/RANKL ratio
also suggests that medullary expansion may act through
enhanced RANKL levels in increasing bone resorption.
Indeed, anemia, by continuously stimulating erythropoietin
synthesis and hence determining bone marrow hyperplasia,
may increase bone resorption through enhanced RNAKL
levels [11]. In addition, the expansion of bone marrow can
cause mechanical interruption of bone, cortical thinning,
bone distortion, and increased fragility [14].
3.3. Hormonal Factors. Hormonal abnormalities, includ-
ing diabetes, thyroid/parathyroid dysfunction, and hypogo-
nadism, are believed to underlie the altered bone turnover
observed in βTM [14]. In female βTM patients, low estrogen
and progesterone levels enhance osteoclast activity and
reduce bone formation, while in males, low testosterone
levels result in a decrease in its stimulatory eﬀects on
osteoblast proliferation and diﬀerentiation [14]. In addi-
tion, insuﬃciency of the GH-IGF-1 axis leads to impaired
osteoblast proliferation and bone matrix formation, while
increasing osteoclast activation [14].
3.4. Genetic Factors. Genetic factors have been shown to play
a role in the pathogenesis of osteopenia/osteoporosis in βTMAnemia 3
patients [14]. For instance, a polymorphism G→To rT T
in the regulatory region of COLIA1 at the recognition site
for transcription factor Sp1 is associated with the presence
of osteoporosis [18]. Sp1 polymorphism occurs more fre-
quently in females but is not speciﬁc to any ethnic group.
In βTM male patients, the presence of the Sp1 mutation is
associated with more severe osteoporosis of the spine and
the hip compared with female patients [18]. In addition,
male βTM patients who are heterozygous or homozygous
at the polymorphic Sp1 site have lower BMD than females
and no improvements in spinal osteoporosis in response to
treatmentwithbisphosphonates[18]. Another study showed
a consistent association between Sp1 polymorphism and
vertebral osteoporosis in a sample of Italian βTM patients,
suggesting the possibility that genotyping of the Sp1 site
could be of clinical value for the identiﬁcation of thalassemic
patients at risk for osteoporosis and fractures [19].
Vitamin D receptor (VDR) polymorphisms at exon 2
(FokI) and intron 8 (BsmI) may be involved in determining
the stature and BMD at femoral neck (FBMD) and lumbar
spine (LBMD) in βTM patients [20]. Indeed, signiﬁcantly
shorter stature and lower LBMD and FBMD were observed
in patients harboring the CC VDR genotype, while signiﬁ-
cant shorter height and lower LBMD have been reported in
prepubertal and pubertal female patients with the BB VDR
genotype [20].
3.5. Iron Overload and Iron-Chelation Therapy. Iron over-
load impairs osteoid maturation and inhibits local mineral-
ization, resulting in focal osteomalacia [14]. In addition, the
incorporation of iron in calcium hydroxyapatite aﬀects the
growth of crystals, leading to defective mineralization [14].
Deferoxamine, the most commonly used iron chelator,
inhibits DNA synthesis, osteoblast and ﬁbroblast prolif-
eration, osteoblast precursor diﬀerentiation, and collagen
formation, while enhancing osteoblast apoptosis [14].
3.6.Miscellanea. Nutritionaldeﬁcitsarecommonlyobserved
in βTM patients and may contribute to bone abnormalities.
In particular, vitamin C deﬁciency can lead to impaired
osteoblast activation and reduced collagen synthesis. Low
vitamin D levels are associated with alterations in cal-
cium/phosphate homeostasis, reduced osteoblast activity,
and increased bone resorption rates [14]. Finally, decreased
levelsofphysicalactivity,duetodiseasecomplicationsand/or
overprotection, negatively inﬂuence bone turnover, leading
to reduced bone formation and enhanced resorption [14].
4.ClinicalFeatures
Bone marrow expansion and extramedullary hemopoiesis
can result in the classical enlargement of cranial and facial
bones with mongoloid appearance, as originally described
by Cooley [1, 3]. Novel transfusion regimens and early
iron-chelating therapy have improved the survival of βTM
patients [21] and have substituted the marked bone abnor-
malities previously described [1] with less severe skeletal
lesions. Yet, sequelae of osteopenia and severe osteoporosis
represent the leading cause of morbidity in βTM patients
[14, 22]. Indeed, the prevalence of osteoporosis in these
patientsisashighas50%, withhigherratesinmales[23,24].
In βTM patients, bone fractures range incidence between
38 and 41% and occur as a consequence of falls in over 50%
ofcases[14,25].Fracturesmorefrequentlyinvolvetheupper
limb,whilespine,hips,andpelvisareaﬀectedin10%ofcases
[14, 25]. Due to the high bone fragility of βTM patients,
fractures of long bones, especially those involving the femur,
should be treated as pathological fractures and require the
stabilization of the entire bone with intramedullary nailing
[26].
βTM patients may also develop the so-called thalassemic
osteoarthropathy, a nonerosive seronegative osteoarthropa-
thy of varying severity, characterized by soft tissue swelling
and pain, usually localized at the ankle joints [27]. Other
skeletal abnormalities relatively common in βTM patients
include lower and upper limb length discrepancy due to
premature fusion of the epiphyseal line [28], axial deviation
of the limbs, osteochondrosis, and short stature [14, 29, 30].
Involvement of the spine is frequent and can manifest as
spinal deformities (e.g., scoliosis, kyphosis), vertebral col-
lapse, cord compression, or intervertebral disc degeneration
[9, 31–35].
5.RadiologicalFeatures
In βTM patients, the most evident radiological changes
are those caused by intense marrow hyperplasia [36]. Such
abnormalities include bone cortex thinning and widening
of intratrabecular spaces, usually seen in hands, but also
in the pelvis and ribs [36]. Extramedullary hemopoietic
tissue sometimes grows beneath the periosteum, producing
a scalloped cortex edge in hands, feet, tibiae, ﬁbulae, knees,
radii, and ulnae. In other cases, extramedullary hemopoietic
tissues can appear as large intrathoracic masses, simulating
paravertebral tumors. In the skull, signiﬁcant thickening of
the cranium can take place, and overgrowth of the facial
bones can impede pneumatization of sinuses [36].
6. Conclusions
Bone changes are frequent in βTM patients and occur
as a consequence of the hematological disorder and its
complications as well as iron overload, iron-chelation ther-
apy, nutritional deﬁcits, and sedentarism. The sequalae of
osteoporosis, especially vertebral and long bone fractures,
represent a major cause of morbidity in these patients.
A better understanding of the pathogenetic mechanisms
underlying bone abnormalities in βTM is needed to develop
targeted treatments. As of now, the early detection of
osteoporosis and the eventual institution of bisphosphonate
treatment are the most eﬀective strategies to reduce the
incidence and severity of skeletal complications. The use
of new-generation iron chelators may avoid the negative
eﬀects of deferoxamine on bone metabolism. Finally, the
identiﬁcation and correction of nutritional and hormonal
deﬁcits and the engagement in physical training programs4 Anemia
should be pursued in βTM patients to reduce the incidence
of osteoporosis and increase overall bone strength.
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